
News|Articles|May 1, 2002
Clarification, strengthening of ziprasidone QTc prolongation warning.
Pfizer has issued a "Dear Healthcare Professional" letter to clarify and strengthen contraindications with its antipsychotic agent ziprasidone HCl (Geodon).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
National Alliance survey shows employers are leaving the ‘big 3’ for other PBMs
2
Novo Nordisk's ziltivekimab falls short to reduce cardiovascular events in phase 3 trial
3
7 takeaways from the MHE webinar on PBM reform and transparency
4
Prior authorization isn’t shrinking. Its savings are
5





















